论文部分内容阅读
目的:评价89SrCl2联合唑来磷酸治疗前列腺癌骨转移临床疗效及不良反应。方法:对去势治疗后的前列腺癌骨转移伴有不同程度骨痛患者34例,使用89SrCl2联合唑来磷酸静脉注射治疗,观察其镇痛效果、骨转移灶的变化、前列腺特异性抗原(PSA)及不良反应等。结果:34例患者接受89Sr联合唑来磷酸治疗后,止痛的总有效率达94.12%,无效5.88%,骨转移灶有明显减少。PSA有不同程度的下降。所有治疗者均未发现严重的不良反应和毒副作用。结论:89SrCl2联合唑来磷酸对去势治疗后的前列腺癌骨转移骨痛的临床止痛疗效明显,特别是对多发骨转移癌伴骨痛患者是一种有效的治疗方法。
Objective: To evaluate the clinical efficacy and adverse reactions of 89SrCl2 combined with zoledronic acid in the treatment of prostate cancer with bone metastases. Methods: Thirty-four patients with bone metastasis of prostate cancer after ovariectomy were treated with different doses of 89SrCl2 and zoledronic acid. The analgesic effects, the changes of bone metastases, the changes of prostate-specific antigen (PSA) ) And adverse reactions. Results: After the treatment of 89Sr combined with zoledronic acid in 34 patients, the total effective rate of analgesic was 94.12% and 5.88%, and the bone metastases were significantly decreased. PSA decreased to varying degrees. No serious adverse reactions and side effects were found in all the patients. Conclusion: 89SrCl2 combined with zoledronic acid has obvious clinical curative effect on castrated bone metastasis of prostate cancer after castration, especially for patients with multiple bone metastases and bone pain.